FDA clears Abbott's FreeStyle InsuLinx blood-glucose monitoring system

ALAMEDA, Calif. — A blood-glucose monitoring system created by Abbott has received clearance from the Food and Drug Administration.

Abbott said the FDA has approved the FreeStyle InsuLinx blood-glucose monitoring system, which includes a touchscreen interface, automated logbook and several personalization features designed to improve the diabetes management experience for patients. What's more, the device also is equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their healthcare providers.

"The new FreeStyle InsuLinx System represents Abbott's latest advancement in delivering innovative products for people with diabetes who use insulin," Abbott Diabetes Care SVP Heather Mason said. "The improved functionality, data sharing tools and personalization features are designed to improve the diabetes management experience for patients. We are excited to make this product available to diabetes patients in the United States."

The FreeStyle InsuLinx aystem will be available to U.S. consumers within the coming months.

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.